Improving early detection of prostate cancer using advanced MRI techniques
Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to Enhance MRI Diagnostic Capabilities in Prostate Cancer
This study is testing a new MRI technique to see if it can help doctors find prostate cancer more accurately during biopsies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 225 (estimated) |
| Sex | Male |
| Sponsor | University of California, San Diego Academic / other |
| Locations | 1 site (La Jolla, California) |
| Trial ID | NCT05882253 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) in enhancing the accuracy of prostate cancer detection during MRI-guided prostate biopsies. It aims to validate the performance of RSI-MRI imaging biomarkers and calibrate their values across different MRI scanner manufacturers. Participants selected for an MRI-fusion prostate needle biopsy will be approached to join the trial, which is designed to provide insights into the clinical benefits of this advanced imaging technique.
Who should consider this trial
Good fit: Ideal candidates are men selected to undergo an MRI-fusion prostate needle biopsy who can provide informed consent.
Not a fit: Patients with a prior diagnosis of prostate cancer, metastatic disease, or those unable to undergo MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate detection of clinically significant prostate cancer, improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using advanced MRI techniques for cancer detection, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Selected to undergo an MRI-fusion prostate needle biopsy of the prostate. * Able to provide informed consent Exclusion Criteria: * prior diagnosis of prostate cancer (Grade Group \>1) * metastatic prostate cancer * prior prostate cancer treatment * contraindication to prostate biopsy (e.g., on anticoagulation that cannot be safely discontinued) * inability to undergo MRI (e.g., too large to be accommodated in a scanner or with an implant incompatible with MRI). * Bilateral hip replacement * Unable to provide informed consent.
Where this trial is running
La Jolla, California
- University of California, San Diego — La Jolla, California, United States (Recruiting)
Study contacts
- Principal investigator: Michael A Liss, MD, PhD — University of California, San Diego
- Study coordinator: Michael A Liss, MD, PhD
- Email: liss@health.ucsd.edu
- Phone: 858-249-1240
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.